Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2601 - PIONEER- Pre-operative wIndOw study of letrozole plus PR agonist Megestrol Acetate versus letrozole aloNE in post-menopausal patients with ER-positive breast cancer

Date

11 Sep 2017

Session

Poster display session

Topics

Cytotoxic Therapy;  Breast Cancer

Presenters

Sanjeev Kumar

Citation

Annals of Oncology (2017) 28 (suppl_5): v43-v67. 10.1093/annonc/mdx362

Authors

S.S. Kumar1, G. Dougall2, A. Vallier2, L. Jones3, W. Qian2, E. Provenzano4, C. Caldas4, P. Pantziarka5, J. Carroll1, R. Baird4

Author affiliations

  • 1 Cambridge Institute, Cancer Research Uk, University of Cambridge, CB2 0RE - Cambridge/GB
  • 2 Cambridge Cancer Trials Centre, Addenbrooke's Hospital, CB2 0QQ - Cambridge/GB
  • 3 Cambridge Breast Cancer Research Unit, University of Cambridge, CB2 0QQ - Cambridge/GB
  • 4 Cambridge Biomedical Campus, Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital, CB2 0QQ - Cambridge/GB
  • 5 Repurposing Drugs In Oncology, Anticancer Fund, Kingston upon Thames/GB
More

Resources

Abstract 2601

Background

Recent preclinical findings have been published which provide new insights into the functional cross-talk between the estrogen receptor (ER) and the progesterone receptor (PR) in breast cancer (Mohammed et al., Nature, 2015). Addition of a PR agonist to anti-estrogens directly modifies ERa chromatin binding and the transcriptional response in breast cancer cells, and is anti-proliferative in vitro and in vivo. Megestrol Acetate (MA), an off-patent semi-synthetic derivative of progesterone, has been licensed for many years as a treatment for ER+ metastatic breast cancer. There is also good evidence for the effectiveness of MA as a supportive therapy to ameliorate endocrine therapy-related hot flushes.

Trial design

PIONEER is a three-arm, open label, multi-centre randomised phase II pre-surgical window trial evaluating effects of 15 days of preoperative therapy with Letrozole (LET), or LET plus MA 40mg, or LET plus MA 160mg in postmenopausal women with newly diagnosed, ER+ HER2- invasive primary breast cancer. Patients are being recruited in Cambridge, with 5-6 other UK sites due to open in q3/4 2017.Table:

213TiP 3-arm randomisation

Arm ALET 2.5mg daily
Arm BLET 2.5mg daily + MA 40mg daily
Arm CLET 2.5mg daily + MA 160mg daily

The primary endpoint is % change in proliferation between baseline and day 15 tumour biopsies, measured by Ki67 immunohistochemical (IHC) assessment. Secondary endpoints include: expression of Aurora Kinase A, Caspase 3 and Androgen receptor/PR/EMT markers by IHC; and safety endpoints. Exploratory endpoints include: transcription factor mapping (ChIP-seq) on paired fresh-frozen tumour samples. Patients are randomised in a 1: 1.5: 1.5 ratio for arms A: B: C. Based on results from previous clinical trials, a mean 66% reduction in Ki67 is anticipated for LET alone (arm A), and a 77.5% reduction for combination arms B and C, based on preclinical data. A recruitment total of 189 patients is required. Pioneer will help determine if there is value in conducting a follow-on adjuvant study to investigate the longer term benefit of combining an aromatase inhibitor with MA, and if so, at what dose (40mg vs. 160mg).

Clinical trial identification

EudraCT Number: 2016-003752-79 MHRA/REC number: v2.0 5th June 2017

Legal entity responsible for the study

Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge

Funding

Anticancer Fund

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.